Development and validation of the epilepsy scale among the system of quality of life instruments for chronic diseases QLICD-EP (V2.0):A multicenter longitudinal study
Epilepsy & Behavior · 2025
DOI: 10.1016/j.yebeh.2025.110444 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Yujie Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Humanities and Management, Key Laboratory for Quality of Life and Psychological Assessment and Intervention, Guangdong Medical University, …. Hauptthemen laut MEDLINE: Quality of Life, Epilepsy, Psychometrics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVES: To develop and evaluate the epilepsy scale among the System of Quality of Life Instruments for Chronic Diseases QLICD-EP(V2.0). METHODS: The QLICD-EP(V2.0) was developed based on a modular approach and programmed decision procedures with multiple nominal and focus group discussions. The data measuring quality of life (QOL) three times before and after treatment of patients with epilepsy (PWE) was used to evaluate the psychometric properties of the scale, including reliability, validity, and responsiveness. RESULTS: The Cronbach's α coefficient of the total scale was 0.902. The test-retest reliability of the total scale was 0.913, and the ICC(95 %CI) of the total scale was 0.953(0.928,0.969). Correlation and confirmatory factor analyses by the structural equation model confirmed good construct validity. Correlation analysis showed good criterion-related validity when using the Short Form-36 Health Survey (SF-36) as a criterion. The paired t-test results showed that the special mentality facet was statistically significant (P < 0.05) before and after the treatment with standard response mean (SRM) being 0.31, there was no statistical significance in other domains and facets with SRM being less than 0.50, which was a low effect. CONCLUSION: QLICD-EP (V2.0) can be used to clinically assess the QOL of PWE in China. Providing a scientific basis for precision medicine and contributing to global health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Humanities and Management, Key Laboratory for Quality of Life and Psychological Assessment and Intervention, Guangdong Medical University, Dongguan 523808, China; The First Dongguan Affiliated Hospital of Guan…
- School of Humanities and Management, Key Laboratory for Quality of Life and Psychological Assessment and Intervention, Guangdong Medical University, Dongguan 523808, China.
- Changzhou Center for Disease Control and Prevention, Changzhou 213000, China.
- The First Dongguan Affiliated Hospital of Guangdong Medical University, Dongguan 523808, China.
- School of Public Health, Kunming Medical University, Kunming 650500, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y., Chi, W., Ding, M., Ding, H., Xu, C., & Wan, C. (2025). Development and validation of the epilepsy scale among the system of quality of life instruments for chronic diseases QLICD-EP (V2.0):A multicenter longitudinal study. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110444
Vancouver
Zhou Y, Chi W, Ding M, Ding H, Xu C, Wan C. Development and validation of the epilepsy scale among the system of quality of life instruments for chronic diseases QLICD-EP (V2.0):A multicenter longitudinal study. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110444
BibTeX
@article{Zhou2025,
author = {Zhou, Yujie and Chi, Wenhua and Ding, Mengke and Ding, Haifeng and Xu, Chuanzhi and Wan, Chonghua},
title = {Development and validation of the epilepsy scale among the system of quality of life instruments for chronic diseases QLICD-EP (V2.0):A multicenter longitudinal study},
journal = {Epilepsy & Behavior},
year = {2025},
doi = {10.1016/j.yebeh.2025.110444}
}
EUVIMED